Nano Dimension Ltd.
3.30%
6,879,708
1643303
Jul 19, 2026
Jul 22, 2026, 04:15 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | CO | 3.30% | 6,879,708 | 6,879,708 | 0 |
Disclosure Items (4)
Ordinary Shares, par value NIS 5.00 per share
Nano Dimension Ltd.
60 TOWER ROAD, WALTHAM, MA, 02451
Item 3 is hereby amended and supplemented as follows: "In open market purchases on July 20, 2026, the Reporting Person expended an aggregate of approximately $1,258,000 (excluding commissions) to purchase call options referencing an aggregate of 8,200,000 Ordinary Shares. The funds used for the purchase of the securities reported in this Schedule 13D were derived from the general working capital of the Reporting Person."
Item 5(a) is hereby amended and restated in its entirety as follows: "(a) The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is stated in Items 11 and 13 on the cover pages hereto. The percentage reported in Item 13 on the cover pages hereto is based upon 210,506,899 Ordinary Shares of the Issuer outstanding as of June 23, 2026, according to the Schedule 14A filed by the Issuer with the SEC on June 30, 2026."
Item 5(b) is hereby amended and restated in its entirety as follows: "(b) Number of shares as to which the Reporting Person has (i) sole power to vote or direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or direct the vote See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto."
Item 5(c) is hereby amended and restated in its entirety as follows: "(c) On July 20, 2026, pursuant to a block sale, the Reporting Person sold 8,200,000 Ordinary Shares at a price per share of $1.55. Other than the foregoing and as set forth in Item 3 and Item 6 of this Schedule 13D, there have been no transactions in the class of securities reported on that were effected by the Reporting Person during the past sixty days or since the most recent filing of Schedule 13D, whichever is less."
Item 5(e) is hereby amended and restated in its entirety as follows: "(e) The Reporting Person ceased to beneficially own more than five percent of the outstanding Ordinary Shares on July 20, 2026."
Item 6 is hereby amended and supplemented as follows: "The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. On July 20, 2026, the Reporting Person engaged in the following transactions: (i) purchased call options referencing an aggregate of 1,350,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026; (ii) purchased call options referencing an aggregate of 6,850,000 Ordinary Shares, having an exercise price of $2.00 per Ordinary Share and expiring on November 20, 2026; (iii) sold put options for an aggregate of approximately $44,999 (excluding commissions) referencing an aggregate of 4,500,000 Ordinary Shares, having an exercise price of $1.00 per Ordinary Share and expiring on August 21, 2026; and (iv) sold put options for an aggregate of approximately $102,998 (excluding commissions) referencing an aggregate of 3,700,000 Ordinary Shares, having an exercise price of $1.50 per Ordinary Share and expiring on August 21, 2026. Following these transactions, the Reporting Person is no longer a party to any options contracts with respect to the Ordinary Shares."